Unituxin FDA Approval History
Unituxin (dinutuximab) is a chimeric monoclonal antibody used for the treatment of pediatric neuroblastoma.
Development Timeline for Unituxin
|Mar 10, 2015||FDA Approves Unituxin (dinutuximab) for Pediatric High-Risk Neuroblastoma|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.